Table 1 Characteristics of 46 patients with spondylarthropathy with at least one uveitis flare, and treated with anti‐tumour necrosis factor (TNF) antibody and soluble TNF receptor between December 1997 and December 2004.
| Characteristics | All patients (n = 46) | Anti‐TNF antibodies infliximab andadalimumab (n = 33) | Soluble TNF receptor etanercept (n = 13) | p Value* |
|---|---|---|---|---|
| Age at first symptoms, mean (SD), years | 25.9 (9.2) | 26.0 (9.6) | 25.9 (8.5) | 0.7 |
| Age at initiation of anti‐TNF treatment, mean (SD), years | 40.0 (10.3) | 41.1 (9.6) | 37.3 (11.8) | 0.3 |
| Male, n (%) | 33 (71.7) | 24 (72.7) | 9 (69.2) | 1 |
| Predominant clinical form of spondylarthropathy for which anti‐TNF was prescribed | 1 | |||
| Axial, n (%) | 33 (71.8) | 23 (69.9) | 10 (76.9) | |
| Peripheral, n (%) | 9 (19.5) | 6 (18.1) | 3 (23.1) | |
| Enthesitic, n (%) | 1 (2.2) | 1 (3.0) | 0 | |
| Undetermined, n (%) | 3 (6.5) | 3 (9.0) | 0 | |
| HLA B27: ± known: n (%)† | 36/40 (90.0) | 26/28 (92.9) | 10/12 (83.3) | 0.6 |
| One concomitant DMARD: yes, n (%) | 15 (32.6) | 12 (36.4) | 3 (23.1) | 0.5 |
| Concomitant corticosteroids: yes, n (%) | 12 (26.1) | 11 (33.3) | 1 (7.7) | 0.1 |
*p Value of the comparison between the patients treated with antibody and those treated with soluble receptor.
†Positivity is given on known data.
SD, standard deviation; DMARD, disease‐modifying anti‐rheumatic drug; HLA, human leucocyte antigen; TNF: tumor necrosis factor.